Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam^® 10%) in patients with immune thrombocytopenia

References

• Cooper N, Bussel J. The pathogenesis of immune thrombocyto-paenic purpura. Br J Haematol 2006; 133: 364–374.
   PubMed Web of Science ®Google Scholar
• Nugent D, McMillan R, Nichol JL, Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585–596.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune throm-bocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393.
   PubMed Web of Science ®Google Scholar
• EMEA. Report of EMEA Expert Meeting on the revisions of thecore SPC and note for guidance for human normal immuonglo-bulin for intravenous administration (IVIg): 5–6 July 2006. London: European Medicines Agency, 2008.
   Google Scholar
• British Society for Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574.–596.
   PubMed Web of Science ®Google Scholar
• American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997; 126: 319–326.
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenousgammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228–1231.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–186.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Pinciaro Pi. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24: 309–314.
   PubMed Web of Science ®Google Scholar
• Schultz C, Bauer M. Immunoglobulins for the treatment of patients with secondary immunodeficiency: long-term investigation confirms excellent tolerability of Octagam®. Eur J Hosp Pharm 2004; 4: 75–77.
   Google Scholar
• Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996; 14(Suppl 15): S115–S119.
   PubMedGoogle Scholar
• Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007; 16: 1038–1047.
   PubMed Web of Science ®Google Scholar
• Haas J, Hommes OR. A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 900–908.
   PubMed Web of Science ®Google Scholar
• Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z Gastroenterol 2007; 45: 605–608.
   PubMed Web of Science ®Google Scholar
• Brennan VM, Salome-Bentley Ni, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133: 247–251.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). Intravenous immunoglobulin: prevention and treatment of disease - NIH consensus development conference statement, 21–23 May 1990.1990: 1–23.
   Google Scholar
• Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. Eur Assoc Hosp Pharm Pract 2007; 13: 66–67.
   Google Scholar
• Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A rando-mized clinical trial. Am J Pediatr Hematol Oncol 1984; 6: 355–361.
   PubMedGoogle Scholar
• Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348–361.
   PubMedGoogle Scholar
• Bussel JB, Kimberly RP, Inman RD et al. Intravenous gammaglo-bulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62: 480–486.
   PubMed Web of Science ®Google Scholar
• Newland AC, Burton I, Cavenagh JD et al. Vigam-S, a solvent/ detergent-treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. Transfus Med 2001; 11: 37–44.
   PubMed Web of Science ®Google Scholar
• Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003; 4: 358–362.
   PubMedGoogle Scholar
• Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglo-bulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84: 45–53.
   PubMed Web of Science ®Google Scholar
• Varga G, Volkova Z, Leibl H et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006; 33: 509–514.
   Web of Science ®Google Scholar
• Piguet D, Tosi C, Luthi JM, Andresen I, Juge O. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immuno-globulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol 2008; 152: 45–49.
   PubMed Web of Science ®Google Scholar
• Robak T, Salama A, Kovaleva L et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombo-cytopenic purpura. Hematology 2009; 14: 227–236.
   PubMed Web of Science ®Google Scholar
• Julia A, Kovaleva L, Loria S et al. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immuno-globulin, in adult patients with chronic idiopathic thrombocyto-penic purpura. Transfus Med 2009; 19: 260–268.
   PubMed Web of Science ®Google Scholar
• Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005; 147: 521–527.
   PubMed Web of Science ®Google Scholar
• Tamminga R, Berchtold W, Bruin M, Buchanan GR, Kuhne T. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol 2009; 146: 180–184.
   PubMed Web of Science ®Google Scholar